The French pharmaceutical giant Sanofi has announced a restructuring plan for its R&D activities and support functions that will result in 1,000 jobs cuts in the next three years in the framework of a restructuring involving other European countries for a total of 1,700 positions. The job reductions will affect support functions, sales and research-related platforms. The cuts will be made in certain sites in the Ile-de-France region in the support functions, at the international headquarters in Paris, at the Val-de-Bièvre campus (Val-de-Marne) or at other locations in France, but above all on tertiary sites. No plant closures are to be expected.
This plan, which will be spread over three years, is not linked to the consequences of Covid-19. It corresponds to a new strategy announced in December 2019. The aim is to make €2 billion in savings and to concentrate on a few promising niches. The company is ending research in diabetes, one of its traditional core businesses, as well as in the cardiovascular field. With this new plan, 'we will continue to dismantle the group and outsource activities, explains a CGT representative. 'Sanofi wants to go from a total of 300 drugs for sale to only about 100. We have the impression that the group only wants to keep what is most profitable'.
The group has cut positions in France in the last years: in 2016 (657 jobs), 2014 (200 jobs), 2012 (270 jobs) and recently in March 2019 (232 jobs). The last job cuts announcement occured in June 2019 with 299 job cuts. A worldwide restructuring was recorded in 2011 (1,400 to 3,000 job cuts in R&D, announced in 2011).